DB04917 : a new drug for the treatment of constipation in the irritable bowel syndrome . DB04917 is a novel drug currently under clinical evaluation for the treatment of irritable bowel syndrome ( IBS ) . DB04917 is a mixed 5-hydroxytryptamine type 4 ( Q13639 ) agonist and 5- Q9H205 receptor antagonist that has a stimulatory effect on gastrointestinal motility and transit , as established by in vivo and in vitro studies . Its therapeutic efficacy , tolerability and safety have been evaluated in diabetic gastroparesis in a single study , as well as in IBS in a few other studies . Phase II studies indicated potential beneficial effects on symptoms and bowel habits in patients with constipation-predominant IBS and mixed-type IBS . The outcome of Phase III studies is currently under evaluation .